$MYOS has recently announced the initiation of a clinical study on their Fortetropin® Dose Response. They're seeking to determine the effect of the supplementation on plasma myostatin levels, to help define the dose response curve. This study could be very beneficial for the company's long-term revenue and product growth. http://www.otcmarkets.com/stock/MYOS/news